Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
Title:
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
Author:
Hamer, Melinda J Houser, Katherine V Hofstetter, Amelia R Ortega-Villa, Ana M Lee, Christine Preston, Anne Augustine, Brooke Andrews, Charla Yamshchikov, Galina V Hickman, Somia Schech, Steven Hutter, Jack N Scott, Paul T Waterman, Paige E Amare, Mihret F Kioko, Victoria Storme, Casey Modjarrad, Kayvon McCauley, Melanie D Robb, Merlin L Gaudinski, Martin R Gordon, Ingelise J Holman, LaSonji A Widge, Alicia T Strom, Larisa Happe, Myra Cox, Josephine H Vazquez, Sandra Stanley, Daphne A Murray, Tamar Dulan, Caitlyn N M Hunegnaw, Ruth Narpala, Sandeep R Swanson II, Phillip A Basappa, Manjula Thillainathan, Jagada Padilla, Marcelino Flach, Britta O’Connell, Sarah Trofymenko, Olga Morgan, Patricia Coates, Emily E Gall, Jason G McDermott, Adrian B Koup, Richard A Mascola, John R Ploquin, Aurélie Sullivan, Nancy J Ake, Julie A Ledgerwood, Julie E